Patients with new-onset RA | General population comparator subjects | HR (95% CI) | |||||
n | PYR | Incidence rate | n | PYR | Incidence rate | ||
Overall | 2386 | 123 360 | 19.3 (17.3 to 21.4) | 9850 | 549 769 | 17.9 (17.0 to 18.9) | 1.01 (0.96 to 1.06) |
Women | 1412 | 86 162 | 16.4 (14.1 to 18.7) | 5607 | 381 574 | 14.7 (13.7 to 15.7) | 1.06 (1.00 to 1.13) |
Men | 974 | 37 197 | 26.2 (21.9 to 30.4) | 4243 | 168 194 | 25.2 (23.3 to 27.2) | 0.93 (0.86 to 1.00) |
Seropositive RA | 1585 | 81 455 | 19.5 (16.9 to 22.0) | 9850 | 549 769 | 17.9 (17.0 to 18.9) | 1.20 (1.13 to 1.28) |
Seronegative RA | 801 | 41 904 | 19.1 (15.7 to 22.5) | 9850 | 549 769 | 17.9 (17.0 to 18.9) | 0.75 (0.70 to 0.82) |
DAS28≤3.2 at diagnosis | 162 | 11 777 | 13.8 (8.7 to 18.9) | 9850 | 549 769 | 17.9 (17.0 to 18.9) | 0.77 (0.64 to 0.92) |
DAS28>3.2 at diagnosis | 1981 | 100 723 | 19.7 (17.3 to 22.0) | 9850 | 549 769 | 17.9 (17.0 to 18.9) | 1.02 (0.97 to 1.07) |
Age at diagnosis (years) | |||||||
<53 | 104 | 44 010 | 2.4 (1.1 to 3.6) | 397 | 201 205 | 2.0 (1.4 to 2.5) | 1.15 (0.92 to 1.44) |
53 to <63 | 355 | 34 028 | 10.4 (7.4 to 13.5) | 1306 | 152 182 | 8.6 (7.3 to 9.9) | 1.20 (1.06 to 1.35) |
63 to <72 | 663 | 25 622 | 25.9 (20.9 to 30.8) | 2418 | 113 358 | 21.3 (19.2 to 23.5) | 1.20 (1.10 to 1.32) |
≥72 | 1264 | 19 697 | 64.2 (55.8 to 72.5) | 5729 | 83 022 | 69.0 (64.9 to 73.1) | 0.86 (0.80 to 0.92) |
Calendar period | |||||||
1997–2001 | 924 | 38 553 | 24.0 (18.2 to 29.7) | 3613 | 172 746 | 20.9 (18.4 to 23.5) | 1.09 (1.01 to 1.18) |
2002–2006 | 815 | 40 849 | 20.0 (15.6 to 24.4) | 3242 | 180 754 | 17.9 (16.0 to 19.9) | 1.02 (0.94 to 1.10) |
2007–2011 | 535 | 33 580 | 15.9 (12.6 to 19.3) | 2372 | 149 719 | 15.8 (14.3 to 17.4) | 0.95 (0.86 to 1.05) |
2012–2015 | 112 | 10 375 | 10.8 (8.0 to 13.6) | 623 | 46 549 | 13.4 (11.9 to 14.9) | 0.77 (0.63 to 0.95) |
DAS28, Disease Activity Score 28-joint counts; PYR, person-years at risk; RA, rheumatoid arthritis; RR, relative risk.